- Home
- AGL vs VRDN Comparison
AGL vs VRDN Comparison
Compare AGL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- VRDN
- Stock Information
- Founded
- AGL 2016
- VRDN 2006
- Country
- AGL United States
- VRDN United States
- Employees
- AGL N/A
- VRDN N/A
- Industry
- AGL Managed Health Care
- VRDN Medical Specialities
- Sector
- AGL Health Care
- VRDN Health Care
- Exchange
- AGL Nasdaq
- VRDN Nasdaq
- Market Cap
- AGL 1.4B
- VRDN 1.6B
- IPO Year
- AGL 2021
- VRDN N/A
- Fundamental
- Price
- AGL $4.08
- VRDN $12.56
- Analyst Decision
- AGL Hold
- VRDN Buy
- Analyst Count
- AGL 18
- VRDN 12
- Target Price
- AGL $3.85
- VRDN $36.44
- AVG Volume (30 Days)
- AGL 5.6M
- VRDN 718.2K
- Earning Date
- AGL 05-06-2025
- VRDN 05-07-2025
- Dividend Yield
- AGL N/A
- VRDN N/A
- EPS Growth
- AGL N/A
- VRDN N/A
- EPS
- AGL N/A
- VRDN N/A
- Revenue
- AGL $6,060,530,000.00
- VRDN $302,000.00
- Revenue This Year
- AGL $2.12
- VRDN N/A
- Revenue Next Year
- AGL $13.99
- VRDN $17,629.40
- P/E Ratio
- AGL N/A
- VRDN N/A
- Revenue Growth
- AGL 40.41
- VRDN N/A
- 52 Week Low
- AGL $1.50
- VRDN $11.40
- 52 Week High
- AGL $7.73
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- AGL 51.56
- VRDN 28.07
- Support Level
- AGL $4.39
- VRDN $14.03
- Resistance Level
- AGL $4.68
- VRDN $15.91
- Average True Range (ATR)
- AGL 0.26
- VRDN 0.67
- MACD
- AGL -0.03
- VRDN -0.19
- Stochastic Oscillator
- AGL 23.31
- VRDN 0.71
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.